Merck's “Quarter Beat” Is a Patent-Reset Reality Check

Merck’s near-term results and outlook can read like an earnings beat, but the value signal is different: the quarter is effectively a stress test of whether Merck can finance oncology continuity while Keytruda’s exclusivity horizon approaches.

In the company’s own reporting, Keytruda biosimilar pressure is not a vague “later” risk. Merck says it expects biosimilar competition between 2028 and 2029, with an initial starting point as early as December 2028 tied to compound patent expiry.

Merck’s 2025 Form 10‑K provides the critical time map investors need.

It states that it expects biosimilar competition between 2028 and 2029, and that biosimilar competition could begin as early as December 2028 when the primary compound patent expires. The same disclosure also references additional composition-of-matter patent expiries later (May 2029 and November 2029), which matters because it implies staggered legal/launch risk rather than a single clean “date.”

The patent cliff affects more than Merck’s P&L. It changes how licensing deals are priced because counterparties anchor to expected peak sales, duration of exclusivity, and transition risk.

When the acquirer is Merck, the market effectively asks: can Merck buy time (through pipeline progression and lifecycle extensions) and still preserve acceptable ROI under a biosimilar timetable? Merck’s own disclosures place the hardest U.S. transition window at 2028–2029. That date acts like a “discount-rate” input for late-stage oncology licensing—especially for assets whose commercial viability depends on long exclusivity runs.

From the fundamentals feed, Merck’s quarterly total revenue is in the mid-$15B–$17B range over recent quarters, with operating income/loss varying across periods. For example, for the quarter ending March 31, 2026, the income statement feed shows total revenue of $16.29B and net loss of $4.24B (quarter-level noise can include one-time items).

Balance-sheet scale is large enough to sustain R&D intensity; the same feed shows total assets of $128.7B as of March 31, 2026 and long-term debt of $46.7B. That supports the idea that Merck can keep funding pipeline transitions while waiting for later-stage outcomes—but it still doesn’t resolve the specific demand-and-price shock window the company states for Keytruda.